Insights

CSL (ASX:CSL) share price heads lower on haemophilia B deal

The CSL Limited (ASX: CSL) share price lower today despite announcing plans to buy rights for novel late-stage gene therapy candidate.
The post CSL (ASX:CSL) share price heads lower on haemophilia B deal appeared first on The Motley Fool Australia. –

A health worker drug testing in a lab to find 'covid-19 vaccine' representing covid shares

The CSL Limited (ASX: CSL) share price is slightly lower today despite announcing plans to buy rights for novel late-stage gene therapy candidate.

In late afternoon trade, the global biotech’s shares are swapping hands for $276.06, down 0.5%.

What did CSL announce?

Investors appear unfazed by the company’s latest release, sending its shares in negative territory.

According to its release, CSL announced it will push forward with its commercialisation and license agreement with Uniqure NV (NASDAQ: QURE).

Founded in 1998, uniQure is a late-stage gene therapy company that is developing etranacogene dezaparvovec (AMT-061) to treat haemophilia B.

The deal, announced last June will give CSL rights to commercialise and sell AMT-061 if approved.

CSL stated that this could be one of the first gene therapies to provide potentially long-term benefits to patients with haemophilia B.

One dose of AMT-061 has shown to increase Factor IX (FIX) plasma levels to a degree that reduces or eliminates the tendency for bleeding for many years. FIX is the blood-clotting protein lacking in people with haemophilia B.

Should AMT-061’s trial be successful, appropriate candidate haemophilia B patients will be able to have a one-time treatment to restore FIX activity to functional levels capable of eliminating the need for frequent and ongoing replacement therapies.

What’s in the deal?

Under the terms of the deal, uniQure will receive an upfront cash payment of US$450 million next week. This will be followed by regulatory and commercial sales milestone payments and royalties.

CSL stated that uniQure will conclude its Phase 3 HOPE-B trial and commence manufacturing for an initial commercial supply. In turn, CSL Behring will look after regulatory submissions and commercialisation.

CSL CEO and managing director, Paul Perreault commented:

We are continuing to build on our legacy of delivering lifesaving innovations in haematology with today’s news. This agreement enables us to take forward a gene therapy that, if approved, has the potential to transform the lives of haemophilia B patients.

Etranacogene dezaparvovec has the potential to be the first-ever gene therapy approved for haemophilia B and help CSL Behring deliver on our ongoing commitment to improving the lives of those living with haemophilia B.

How has the CSL share price performed lately?

Since early March, CSL shares have begun their accent to levels achieved in mid-January. Year-to-date performance is marginally lower at around 2%, however, it seems the worst is behind the company. Just yesterday, CSL released its presentation for the upcoming Macquarie Group Ltd (ASX: MQG) conference, citing an update on plasma collections.

CSL has a market capitalisation of around $126 billion, with approximately 455.1 million shares on issue.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post CSL (ASX:CSL) share price heads lower on haemophilia B deal appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!